Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8191 to 8205 of 9023 results

  1. Suspected cancer (QS124)

    April 2026: We have withdrawn this quality standard following the launch of the updated NICE guideline on suspected cancer: recognition and referral. An updated NICE quality standard for suspected cancer is being developed.  For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  2. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

    NICE guideline
    Discontinued

  3. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  6. Fertility problems: assessment and treatment (CG156)

    This guideline has been updated and replaced by NICE guideline NG257.

    Withdrawn guideline

  7. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    Discontinued Reference number: GID-TA11146

    Technology appraisal guidance
    Discontinued

  8. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

    Safe staffing guideline
    Discontinued

  13. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued Reference number: GID-MT510

    Medical technologies guidance
    Discontinued

  14. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued Reference number: GID-TA10088

    Technology appraisal guidance
    Discontinued

  15. OraQuick® HCV Rapid Antibody Test (discontinued)

    Discontinued Reference number: GID-MT117

    Medical technologies guidance
    Discontinued